Form 4 for ABOS Acumen Pharmaceuticals, Inc.
Accepted 2023-01-03 00:00:00 ET · period of report 2022-12-29 · accession 0001209191-23-000327 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-03 | 2022-12-29 | ABOS | Zuga Matt | CFO, Chief Business Off | M - OptEx | $1.19 | +50.0K | 76.2K | +191% | +$59.5K |
| D | 2023-01-03 | 2022-12-29 | ABOS | Zuga Matt | CFO, Chief Business Off | M - OptEx | $0.00 | -50.0K | 401.4K | -11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-29 | M | A | 50,000 | $1.19 | 76,187 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2022-12-29 | M | D | 50,000 | $0.00 | 401,369 | D | $1.19 · — to 2031-01-03 | 50,000 Common Stock | (F1) 25% of the shares underlying the option vested and became exercisable on January 1, 2022; the remainder vested or shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date. |